Dicot Pharma receives FDA clearance to start Phase 2b study of LIB-01 in US

CeleCor Therapeutics submits final section of zalunfiban (Disaggpro) New Drug Application to US FDA

Vascarta announces VAS-101 Phase I results in sickle cell disease patients

Cirius Therapeutics commences enrolment and dosing for Phase 2 study of CIR-0602K in type 1 diabetes

Lundbeck to present new Vyepti and bocunebart migraine data at EAN 2026

Thalia Therapeutics acquires Sanmirna and raises GBP2.75m to advance AML RNA therapy

Circio and Tcelltech partner on next-generation CAR-T cell therapy research

Essange Reagents and Gentian Diagnostics agree collaboration on diagnostic assay development

Haisco agrees licensing deal with Nuvectis for two drug candidates

Psilera introduces new synthetic platform to aid neuroplastogen discovery

EU approves MAVIRET for acute hepatitis C treatment

EU approves Cenrifki for secondary progressive multiple sclerosis without relapses

Japan approves Wayrilz for immune thrombocytopenia treatment

Nura Bio completes USD73.8m Series B financing, advances clinical-stage SARM1 inhibitor programmes

Oxford BioTherapeutics reports progress in Boehringer Ingelheim partnered programmes